Dimethyl bisphenolate inhibits ovarian cancer growth by regulating the PI3K/AKT/mTOR signaling pathway
Bioorganic Chemistry · 2026-06 · 174 · 109769
DOI: 10.1016/j.bioorg.2026.109769 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-06. Verfasst von Mengke Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Binzhou Medical University, Yantai 264003, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents, Benzhydryl Compounds. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Youth Innovation Technology Project of Higher School in Shandong Province, Shandong Province Natural Science Foundation.
Abstract (Originalsprache)
Ovarian cancer is a leading gynecological malignancy with a poor patient survival rate. The current therapeutic regimen primarily relies on chemotherapy. However, most patients experience relapse and develop chemoresistance. Therefore, there is an urgent need to develop new anti-ovarian cancer compounds and scalable production processes. Dimethyl bisphenolate (DMB), a novel compound that we synthesized, is a phenolic acid derivative based on the neolignan backbone. The compound was produced by degrading and esterifying salvianolic acid B, the primary active ingredient in Salvia miltiorrhiza Bge. This study evaluated the anti-ovarian cancer activity of DMB through in vitro and in vivo experiments. DMB effectively inhibited the proliferation and migration of ovarian cancer cells in vitro. Mechanistic studies demonstrated that DMB suppresses ovarian cancer cell growth by regulating the PI3K/AKT/mTOR signaling pathway, impairing energy metabolism, and inducing cell cycle arrest and apoptosis. In vivo experiments further confirmed DMB significantly inhibited tumor growth in a human ovarian cancer nude mouse xenograft model. Overall, the significant anti-ovarian cancer effect demonstrated, the underlying mechanisms elucidated, and the scalable preparation technology established indicate that DMB is a promising therapeutic candidate for treating ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Binzhou Medical University, Yantai 264003, China.
- Binzhou Medical University, Yantai 264003, China; Shandong Provincial Key Medical and Health Laboratory of Stem Cell and Regenerative Medicine Translation, Liaocheng People's Hospital, Liaocheng, Shandong 252000, China.
- Division of Infectious Diseases and Global Health, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, United States.
- Binzhou Medical University, Yantai 264003, China. Electronic address: qu_guiwu@163.com.
- Binzhou Medical University, Yantai 264003, China; Shandong Province Key Laboratory of Complex Medical Intelligence and Aging, Yantai 264003,China. Electronic address: songshuling0223@163.com.
- Binzhou Medical University, Yantai 264003, China. Electronic address: caoqizhi@126.com.
Förderung
- National Natural Science Foundation of China
- Youth Innovation Technology Project of Higher School in Shandong Province
- Shandong Province Natural Science Foundation
Zitieren
APA
Liu, M., Liu, Y., Xue, P., Chen, R., Zhang, H., Hao, M., Wang, Z., Zhang, X., Xu, L., Li, R., An, J., Qu, G., Song, S., & Cao, Q. (2026). Dimethyl bisphenolate inhibits ovarian cancer growth by regulating the PI3K/AKT/mTOR signaling pathway. Bioorganic Chemistry, 174, 109769. https://doi.org/10.1016/j.bioorg.2026.109769
Vancouver
Liu M, Liu Y, Xue P, Chen R, Zhang H, Hao M, et al. Dimethyl bisphenolate inhibits ovarian cancer growth by regulating the PI3K/AKT/mTOR signaling pathway. Bioorganic Chemistry. 2026;174:109769. doi:10.1016/j.bioorg.2026.109769
BibTeX
@article{Liu2026,
author = {Liu, Mengke and Liu, Yunyi and Xue, Pengyuan and Chen, Runpeng and Zhang, Huachang and Hao, Mingtao and Wang, Zhiwei and Zhang, Xueyang and Xu, Liuyang and Li, Ruozhu and An, Jing and Qu, Guiwu and Song, Shuling and Cao, Qizhi},
title = {Dimethyl bisphenolate inhibits ovarian cancer growth by regulating the PI3K/AKT/mTOR signaling pathway},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {174},
pages = {109769},
doi = {10.1016/j.bioorg.2026.109769}
}
EUVIMED